A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a Background Therapy Regimen of 2 Nucleoside Reverse‐Transcriptase Inhibitors in Patients with Initially Suppressed Viral Loads | Zendy

Alessandro CozziLepri | Zendy; Andrea De Luca | Zendy; Andrew Phillips | Zendy; Marco Bongiovanni | Zendy; Simona Di Giambenedetto | Zendy; Maurizio Mena | Zendy; Maria Cristina Moioli | Zendy; M. Arlotti | Zendy; Laura Sighinolfi | Zendy; Pasquale Narciso | Zendy; Miriam Lichtner | Zendy; Roberto Cauda | Zendy; Antonella d’Arminio Monforte | Zendy

Open Access

A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a Background Therapy Regimen of 2 Nucleoside Reverse‐Transcriptase Inhibitors in Patients with Initially Suppressed Viral Loads

Author(s) -

Alessandro CozziLepri,

Andrea De Luca,

Andrew Phillips,

Marco Bongiovanni,

Simona Di Giambenedetto,

Maurizio Mena,

Maria Cristina Moioli,

M. Arlotti,

Laura Sighinolfi,

Pasquale Narciso,

Miriam Lichtner,

Roberto Cauda,

Antonella d’Arminio Monforte

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/504265

Subject(s) - abacavir , efavirenz , stavudine , lamivudine , didanosine , medicine , zidovudine , reverse transcriptase inhibitor , regimen , viral load , virology , pharmacology , gastroenterology , antiretroviral therapy , human immunodeficiency virus (hiv) , viral disease , virus , hepatitis b virus

Our objective was to compare the rate of viral rebound and therapy failure in patients receiving abacavir or efavirenz as the third drug (in addition to 2 non-abacavir nucleosides) in combination antiretroviral therapy (cART) and to compare the rate of metabolic alteration associated with these regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research